Diverse antimicrobial killing by Enterococcus faecium E 50-52 bacteriocin.
An effective bacteriocin was identified and characterized. Lactic acid bacteria were screened against Campylobacter jejuni. One bacteriocin producer, Enterococcus faecium (NRRL B-30746), was studied. The isolate was grown, and the bacteriocin was purified to single-band homogeneity. Biochemical traits indicated that the peptide was a Class IIa bacteriocin, and it was named E 50-52. The bacteriocin had a molecular weight of 3339.7 and an isoelectric point of 8.0. The minimal inhibitory concentrations of E 50-52 against C. jejuni, Yersinia spp., Salmonella spp., Escherichia coli O157:H7, Shigella dysenteriae, Morganella morganii, Staphylococcus spp., and Listeria spp. ranged from 0.025 to 32 microg/mL. In therapeutic broiler trials, oral treatment with E 50-52 reduced both C. jejuni and Salmonella enteritidis by more than 100,000-fold in the ceca, and systemic S. enteritidis was reduced in the liver and spleen. The wide range of antibacterial activity of bacteriocin E 50-52 against pathogens provides a promising alternative to antibiotics.
Svetoch
Edward A
EA
State Research Center for Applied Microbiology and Biotechnology (SRCAMB), Obolensk, Russian Federation.
Eruslanov
Boris V
BV
Perelygin
Vladimir V
VV
Mitsevich
Evgeni V
EV
Mitsevich
Irina P
IP
Borzenkov
Valery N
VN
Levchuk
Vladimir P
VP
Svetoch
Olga E
OE
Kovalev
Yuri N
YN
Stepanshin
Yuri G
YG
Siragusa
Gregory R
GR
Seal
Bruce S
BS
Stern
Norman J
NJ
D000595:Amino Acid Sequence; D000818:Animals; D000890:Anti-Infective Agents / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D001430:Bacteriocins / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D002167:Campylobacter / Q000187:drug effects; D002645:Chickens / Q000382:microbiology; D016984:Enterococcus faecium / Q000254:growth & development / Q000378:metabolism*; D007526:Isoelectric Point; D008087:Listeria / Q000187:drug effects; D008969:Molecular Sequence Data; D008970:Molecular Weight; D016415:Sequence Alignment; D013210:Staphylococcus / Q000187:drug effects; D015007:Yersinia / Q000187:drug effects
D000890:Anti-Infective Agents; D001430:Bacteriocins; C529386:bacteriocin E 50-52, Enterococcus faecium